Adverse delayed cutaneous events have been noted significantly (P < 0.05) more often with a dimeric nonionic agent (16.4%) than with a monomeric nonionic contrast agent (9.7%) [ 5].
These data show that in this district in South Africa where care by TB and ART services was not integrated and was delivered in different localities, potentially adverse delays in starting ART in patients with HIV-associated TB were largely attributable to the prolonged time between diagnosis in the TB clinic and patient access to the ART clinic.
Around three-quarters (8/11) of patients presented a delayed-onset cardiac adverse event (delay ≥2 years).
The consequences of discontinuity of care are linked to increased cost and length of hospital stay, readmissions, poorer patient satisfaction, adverse events, delays in treatment and diagnosis, inappropriate treatment and omission of care [ 9, 10].
Multivariate analyses indicated that the adverse impact of delay in presentation on survival was attributable to an association between longer delays and more advanced stage.
Early recognition and management of risk factors can prevent or delay adverse outcomes.
Failure of the initial treatment, often due to inadequate benefit or adverse events, can delay treatment optimisation and disease stabilisation.
Establishing a clinically appropriate time that patients can safely wait for the operation is generally perceived as a method to prevent adverse outcomes of delay [ 4].
Charlson score ⩽2 vs >2 did not influence adverse events, chemotherapy delay, CRT dose, or CCR to CRT, but only overall survival.
A series of delays, adverse weather, planning wrangles and technical issues mean it will be months – at the earliest – before the controversial project is completed.
